



www.genfit.com

GFT505: PROOF OF EFFICACY IN NASH

PUBLISHED IN *HEPATOLOGY*

- *Hepatology* is the official journal of the American Association for the Study of Liver Diseases (AASLD).
- The scientific article can be consulted on the *Hepatology* web-site.

Lille (France), Boston (Massachusetts, United States), May 27, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the publication in *Hepatology* of data reporting the efficacy and mechanism of action of GFT505 in different animal models of NASH*.

The manuscript includes comprehensive data showing that GFT505 has both preventive and curative effects on hepatic steatosis, inflammation, and fibrosis. These beneficial effects are associated with an improvement in liver dysfunction markers in the blood, and with a decrease in liver expression of pro-inflammatory and pro-fibrotic genes. The results also demonstrate the interest of GFT505 as a mixed activator of the PPAR α and PPAR δ receptors as compared to reference molecules. Moreover, a combined analysis of four Phase IIa studies performed in dyslipidemic, pre-diabetic, and/or diabetic patients confirmed the beneficial effects of GFT505 on hepatic dysfunction markers in man.

After the review of the data by independent experts selected by the journal, the manuscript is published under the title: 'Hepato-protective effects of the dual PPAR α / δ agonist GFT505 in rodent models of NAFLD/NASH', B. Staels et al., DOI: 10.1002/hep.26461. The accepted manuscript may be consulted on the 'Hepatology' web-site prior to final publication (<http://onlinelibrary.wiley.com/doi/10.1002/hep.26461/abstract>).

Hepatology is the most important scientific journal in the field of liver diseases. The journal publishes original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the Editorial Board of the journal selects the best articles in immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism.

Dr. Rémy Hanf, EVP, Product Development, declared: "The publication of this article in an internationally renowned scientific journal such as *Hepatology* validates the importance of the beneficial effects observed with GFT505, and confirms its therapeutic potential in NASH."

***About NAFLD/NASH:**

NAFLD (non-alcoholic fatty liver disease) and in particular NASH (non-alcoholic steatohepatitis) are serious liver diseases that can lead to cirrhosis and liver cancer. The development of NAFLD/NASH is associated with the pathophysiological process of insulin resistance in patients that are overweight and/or diabetic. NAFLD is believed to affect 70-80% of diabetic patients, and progresses to chronic liver disease (NASH) in 20-50% of cases. Mortality due to liver disease is thus 2-3-fold higher in the diabetic population than in the overall population. The NASH market was estimated at 615 \$M in 2010 and should reach 2,008 \$M in 2018.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr